Trinity Biotech
TRIB
56 hedge funds and large institutions have $89.6M invested in Trinity Biotech in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.17% less ownership
Funds ownership: 3.32% → 3.15% (-0.17%)
4% less capital invested
Capital invested by funds: $93.7M → $89.6M (-$4.16M)
16% less funds holding
Funds holding: 67 → 56 (-11)
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $101K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$8.01M |
| 2 |
SM
Senvest Management
New York
|
+$1.3M |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$764K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$421K |
| 5 |
Renaissance Technologies
New York
|
+$376K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
-$1.81M |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
-$1.34M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$818K |
| 4 |
RA
Royce & Associates
New York
|
-$630K |
| 5 |
JP Morgan Chase
New York
|
-$540K |
TRIB Hedge Fund Activity: Q2 2017 in Review
56 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2017, worth a combined $89.6M — down 4.4% from $93.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TRIB and 3 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $8.01M. The largest seller was Fondren Management, cutting an estimated $1.81M.
- 56 institutional investors held Trinity Biotech (TRIB) as of Q2 2017, down from 67 in Q1 2017.
- Funds reported $89.6M of Trinity Biotech stock for Q2 2017, down 4.4% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2017 and 12 closed out, a net change of -9 holders.
- The largest Trinity Biotech buyer in Q2 2017 was Janus Henderson Group, an estimated $8.01M added.
- The largest Trinity Biotech seller in Q2 2017 was Fondren Management, an estimated $1.81M sold.
Based on aggregated 13F filings for Q2 2017.